CA2390685A1 - Methodes et compositions permettant d'inhiber la croissance cellulaire neoplasique - Google Patents

Methodes et compositions permettant d'inhiber la croissance cellulaire neoplasique Download PDF

Info

Publication number
CA2390685A1
CA2390685A1 CA002390685A CA2390685A CA2390685A1 CA 2390685 A1 CA2390685 A1 CA 2390685A1 CA 002390685 A CA002390685 A CA 002390685A CA 2390685 A CA2390685 A CA 2390685A CA 2390685 A1 CA2390685 A1 CA 2390685A1
Authority
CA
Canada
Prior art keywords
present
methods
polypeptides
compositions
cell growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002390685A
Other languages
English (en)
Other versions
CA2390685C (fr
Inventor
Avi J. Ashkenazi
Audrey Goddard
Austin L. Gurney
Mary A. Napier
Colin K. Watanabe
William I. Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech, Inc.
Avi J. Ashkenazi
Audrey Goddard
Austin L. Gurney
Mary A. Napier
Colin K. Watanabe
William I. Wood
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2000/000376 external-priority patent/WO2000053755A2/fr
Priority claimed from PCT/US2000/004342 external-priority patent/WO2000078961A1/fr
Priority claimed from PCT/US2000/005841 external-priority patent/WO2000053758A2/fr
Priority claimed from PCT/US2000/008439 external-priority patent/WO2000073454A1/fr
Priority claimed from PCT/US2000/020710 external-priority patent/WO2001009327A2/fr
Application filed by Genentech, Inc., Avi J. Ashkenazi, Audrey Goddard, Austin L. Gurney, Mary A. Napier, Colin K. Watanabe, William I. Wood filed Critical Genentech, Inc.
Publication of CA2390685A1 publication Critical patent/CA2390685A1/fr
Application granted granted Critical
Publication of CA2390685C publication Critical patent/CA2390685C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002390685A 2000-01-06 2000-11-08 Methodes et compositions permettant d'inhiber la croissance cellulaire neoplasique Expired - Lifetime CA2390685C (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
PCT/US2000/000376 WO2000053755A2 (fr) 1999-03-08 2000-01-06 Compositions et procedes pour le traitement de tumeur
USPCT/US00/00376 2000-01-06
PCT/US2000/004342 WO2000078961A1 (fr) 1999-06-23 2000-02-18 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
USPCT/US00/04342 2000-02-18
PCT/US2000/005841 WO2000053758A2 (fr) 1999-03-08 2000-03-02 Compositions et methodes de traitement des maladies immunitaires
USPCT/US00/05841 2000-03-02
USPCT/US00/08439 2000-03-30
PCT/US2000/008439 WO2000073454A1 (fr) 1999-06-02 2000-03-30 Polypeptides transmembranaires secretes et acides nucleiques codants pour ceux-ci
PCT/US2000/020710 WO2001009327A2 (fr) 1999-07-28 2000-07-28 Procede de prevention de la deterioration ou de la mort des cellules de la retine et de traitement des troubles oculaires
USPCT/US00/20710 2000-07-28
PCT/US2000/030952 WO2001049715A2 (fr) 2000-01-06 2000-11-08 Methodes et compositions permettant d'inhiber la croissance cellulaire neoplasique

Publications (2)

Publication Number Publication Date
CA2390685A1 true CA2390685A1 (fr) 2001-07-12
CA2390685C CA2390685C (fr) 2008-04-22

Family

ID=27533357

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002390685A Expired - Lifetime CA2390685C (fr) 2000-01-06 2000-11-08 Methodes et compositions permettant d'inhiber la croissance cellulaire neoplasique

Country Status (4)

Country Link
EP (1) EP1244784A2 (fr)
JP (1) JP4280444B2 (fr)
CA (1) CA2390685C (fr)
WO (1) WO2001049715A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083791B2 (en) 1999-03-25 2006-08-01 Genesis Research & Development Corporation Limited Methods for enhancing immune responses by fibroblast growth factor receptor 5 polypeptides
US6797271B2 (en) 1999-03-25 2004-09-28 Genesis Research & Development Corporation Limited Methods for enhancing immune responses by fibroblast growth factor receptor 5 polypeptides
AU2002217838A1 (en) 2000-11-14 2002-05-27 Bristol-Myers Squibb Company A human serpin secreted from lymphoid cells LSI-01
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
JP2007524566A (ja) 2002-12-20 2007-08-30 エンカム ファーマシューティカルズ アクティーゼルスカブ レセプターとリガンドの間の相互作用の調節の方法
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
WO2013167153A1 (fr) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Anticorps utiles dans le diagnostic du cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226799A (en) * 1987-11-06 1991-08-27 Oncogen Breast cancer inhibitory factor and method for inhibiting proliferation of neoplastic cells and compositions therefor
US5814307A (en) * 1989-04-10 1998-09-29 Bristol-Myers Squibb Company Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6
US5416192A (en) * 1990-04-03 1995-05-16 Bristol-Myers Squibb Company Epithelins: novel cysteine-rich growth modulating proteins
CA2080008C (fr) * 1990-04-27 2002-07-02 Koichi Igarashi Muteine hydrosoluble du recepteur de facteur de croissance des fibrolastes
WO2001009327A2 (fr) * 1999-07-28 2001-02-08 Genentech, Inc. Procede de prevention de la deterioration ou de la mort des cellules de la retine et de traitement des troubles oculaires
CA2328895A1 (fr) * 1998-06-02 1999-12-09 Genentech, Inc. Proteines membranaires et acides nucleiques codant ces proteines
WO2000046380A2 (fr) * 1999-02-08 2000-08-10 Chiron Corporation Fusion du recepteur du facteur de croissance des fibroblastes avec une immunoglobuline
AU2495200A (en) * 1999-03-08 2000-09-28 Genentech Inc. Compositions and methods for the treatment of tumor
CA2383254A1 (fr) * 1999-06-02 2000-12-07 Genentech, Inc. Polypeptides transmembranaires secretes et acides nucleiques codants pour ceux-ci
WO2001000661A2 (fr) * 1999-06-25 2001-01-04 Genset Proteine 1 associee a un transporteur de carnitine (ccrp-1)

Also Published As

Publication number Publication date
WO2001049715A2 (fr) 2001-07-12
WO2001049715A3 (fr) 2002-04-04
JP2004500071A (ja) 2004-01-08
CA2390685C (fr) 2008-04-22
JP4280444B2 (ja) 2009-06-17
EP1244784A2 (fr) 2002-10-02

Similar Documents

Publication Publication Date Title
WO2000073348A3 (fr) Procedes et compositions visant a inhiber la proliferation des cellules cancereuses
WO2000037638A3 (fr) Methodes permettant d'inhiber la croissance de cellules neoplasiques
HK1114636A1 (en) 1l-17 homologous polypeptides and therapeutic uses thereof
EP1690872A3 (fr) Composition et procédés de diagnostic de tumeurs
WO2002026822A3 (fr) Compositions pumpcn et leurs utilisations
WO1999060127A3 (fr) Polypeptides homologues de il-17 et utilisations therapeutiques de ceux-ci
WO2000032778A3 (fr) Methodes et compositions permettant d'inhiber la croissance de cellules neoplasiques
CA2390685A1 (fr) Methodes et compositions permettant d'inhiber la croissance cellulaire neoplasique
WO2002016611A3 (fr) Polypeptides d'interleukine-22, acides nucleiques codant pour lesdits polypeptides et methode permettant de traiter les affections pancreatiques
WO2000037640A3 (fr) Compositions et methodes de traitement d'une tumeur
EP2075335A3 (fr) Procédés et compositions d'inhibition de la croissance de cellules néoplasiques
EP1873244A3 (fr) Procédés et compositions d'inhibition de la croissance de cellules néoplasiques
EP1666497A3 (fr) Polypeptide, acides nucléiques le codant, et leur utilisation pour le diagnostic du cancer
KR100515858B1 (en) PRO617 Polypeptides
CA2382302A1 (fr) Acide nucleique et polypeptide codant servant a inhiber l'angiogenese tumorale
EP1241186A3 (fr) Protéine gas-6 (growth arrest-specific gene 6) humaine et acides nucléiques le codant
EP1241187A3 (fr) Protéine semblable à fibulin et acides nucléiques le codant
EP1657254A3 (fr) Polypeptide, acides nucléiques le codant, et leur utilisation pour le diagnostic du cancer
EP1241250A3 (fr) Protéine humaine semblable à la déhydrgénase et acides nucléiques le codant
KR100515855B1 (en) PRO351 Polypeptides
KR100515856B1 (en) PRO618 Polypeptides
EP1277833A3 (fr) Homologue de Costal-2
EP1865061A3 (fr) Polypeptides allogéniques IL-17 et utilisations thérapeutiques

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20201109